Featured Research

from universities, journals, and other organizations

Adding chemotherapy following radiation treatment improves survival for adults with a slow-growing type of brain tumor, study shows

Date:
February 5, 2014
Source:
National Cancer Institute (NCI) at NIH
Summary:
Adults with low-grade gliomas, a form of brain tumor, who received a chemotherapy regimen following completion of radiation therapy, lived longer than patients who received radiation therapy alone, according to long-term follow-up results from a randomized controlled clinical trial.

Drawing of a glioma in the brain.
Credit: National Cancer Institute (NCI) at NIH

Adults with low-grade gliomas, a form of brain tumor, who received a chemotherapy regimen following completion of radiation therapy, lived longer than patients who received radiation therapy alone, according to long-term follow-up results from a National Institutes of Health-supported randomized controlled clinical trial.

Since all three chemotherapy drugs in the regimen are commercially available, the treatment used in the clinical trial is available for use now. However, this form of chemotherapy is associated with some toxicities, such as reduced white blood cell counts leading to increased infection risk, and trial investigators recommend that it should be utilized only by physicians experienced with managing the side-effects that may occur.

Low-grade gliomas grow more slowly and have a better outcome than the more common type of brain tumor in adults, which is classified as glioblastoma.

The Radiation Therapy Oncology Group (RTOG), a clinical trials organization funded by the National Cancer Institute (NCI), part of NIH, and NCI are making the results public today because a long-term follow-up analysis showed significantly longer survival for those people on the trial who received chemotherapy. Full details from this analysis are to be presented at a scientific meeting in 2014 and in a peer-reviewed publication.

The study, RTOG 9802, enrolled 251 patients with low-grade gliomas between October 1998 and June 2002 to address the role of chemotherapy following radiation treatment. Patients enrolled were at high risk compared to other low-grade glioma patients because they were 40 years of age or older or had a less than complete surgical removal of their tumor if they were under 40 years of age.

All patients started treatment with surgery followed by radiation therapy. By random assignment, half of patients stopped treatment after radiation therapy and the other half received six cycles of chemotherapy after completing radiation therapy. Patients receiving chemotherapy got three drugs: procarbazine (P); CCNU (C), which generically is known as lomustine; and vincristine (V). This chemotherapy, termed PCV, was given over 21 days and repeated every eight weeks for a total of six cycles.

A significant improvement in overall survival was noted for study participants who received PCV chemotherapy plus radiation therapy (13. 3 years median survival time) compared to those receiving radiation therapy alone (7.8 years median survival time), which is a difference of 5.5 years. Median follow-up after initial enrollment has been almost 12 years.

Analysis of how patients are doing based upon the molecular and genetic characteristics of their tumors is ongoing. These studies will be important since molecular characteristics of related brain tumors have been able to identify patients most likely to benefit from chemotherapy.

"The results of this study are practice-changing," said co-lead investigator Jan Buckner, M.D., professor of oncology, Mayo Clinic, Rochester, Minn. "Additionally, ongoing analysis of patient tumor samples should allow us to further identify the patients who will, and who will not, benefit from chemotherapy, taking yet another step toward individualized therapy."

Edward Shaw, M.D., co-lead investigator and radiation oncologist at Wake Forest School of Medicine, Winston-Salem, NC, noted, "Patients who are deemed appropriate candidates for radiation therapy should be encouraged to receive chemotherapy as well, understanding both the potential benefits and risks."

RTOG 9802 was sponsored by NCI and was designed and conducted by RTOG in collaboration with three other NCI cooperative groups (SWOG, ECOG-ACRIN, and the Alliance for Clinical Trials in Oncology). RTOG will work as a component of a new network group, NRG Oncology, effective March 2014.

"This trial would not have been done in the United States without a large national network of investigators brought together through the NCI-supported Cooperative Group program that was capable of enrolling patients with a relatively uncommon cancer like low-grade glioma," said Jeff Abrams, M.D., clinical director of NCI's Division of Cancer Treatment and Diagnosis. "These findings also are an example of how combining available treatments can produce a significant improvement in clinical outcome."

It is estimated that over 23,000 people will be diagnosed with primary brain tumors in the United States in 2014 and that 10 percent to 15 percent will have low-grade gliomas.


Story Source:

The above story is based on materials provided by National Cancer Institute (NCI) at NIH. Note: Materials may be edited for content and length.


Cite This Page:

National Cancer Institute (NCI) at NIH. "Adding chemotherapy following radiation treatment improves survival for adults with a slow-growing type of brain tumor, study shows." ScienceDaily. ScienceDaily, 5 February 2014. <www.sciencedaily.com/releases/2014/02/140205103147.htm>.
National Cancer Institute (NCI) at NIH. (2014, February 5). Adding chemotherapy following radiation treatment improves survival for adults with a slow-growing type of brain tumor, study shows. ScienceDaily. Retrieved September 19, 2014 from www.sciencedaily.com/releases/2014/02/140205103147.htm
National Cancer Institute (NCI) at NIH. "Adding chemotherapy following radiation treatment improves survival for adults with a slow-growing type of brain tumor, study shows." ScienceDaily. www.sciencedaily.com/releases/2014/02/140205103147.htm (accessed September 19, 2014).

Share This



More Health & Medicine News

Friday, September 19, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com
What HealthKit Bug Means For Your iOS Fitness Apps

What HealthKit Bug Means For Your iOS Fitness Apps

Newsy (Sep. 18, 2014) Apple has delayed the launch of the HealthKit app platform, citing a bug. Video provided by Newsy
Powered by NewsLook.com
U.S. Food Makers Surpass Calorie-Cutting Pledge

U.S. Food Makers Surpass Calorie-Cutting Pledge

Newsy (Sep. 18, 2014) Sixteen large food and beverage companies in the United States that committed to cut calories in their products far surpassed their target. Video provided by Newsy
Powered by NewsLook.com
Residents Vaccinated as Haiti Fights Cholera Epidemic

Residents Vaccinated as Haiti Fights Cholera Epidemic

AFP (Sep. 18, 2014) Haitians receive the second dose of the vaccine against cholera as part of the UN's vaccination campaign. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins